New Drug Doubles Survival in Advanced Pancreatic Cancer, Landmark Trial Shows
Updated
Updated · The Washington Post · Apr 22
New Drug Doubles Survival in Advanced Pancreatic Cancer, Landmark Trial Shows
52 articles · Updated · The Washington Post · Apr 22
Revolution Medicines’ experimental drug daraxonrasib has doubled median survival in patients with metastatic pancreatic cancer compared to standard chemotherapy in a Phase 3 trial.
The drug targets KRAS mutations, present in most pancreatic cancers, and showed a median overall survival of 13.2 months versus 6.7 months for chemotherapy.
While some patients experienced significant side effects, the results mark a major advance in treating a cancer long considered nearly untreatable.
After 40 years of failure, have scientists finally cracked pancreatic cancer’s 'undruggable' master gene?
Can emerging cancer vaccines and new blood tests finally make pancreatic cancer a preventable disease?
With an FDA 'ultra-fast' track, could this new cancer pill be available to patients in just weeks?
A former U.S. senator called the breakthrough pill 'nasty.' What is the real cost of longer survival?
Why did a company's stock fall after it announced doubling survival rates for a deadly cancer?